Liver Disease Spectrum (hepatic Cancer Progression) Tissue Array, Including TNM, Clinical Stage And Pathology Grade, 80 Cases/80 Cores, Replacing LV8011|ヒト組織アレイ
掲載日情報：2016/03/01 現在Webページ番号：179095
US Biomax社は、組織アレイを提供しているメーカーです。
US Biomax社のヒト組織アレイ(Liver Disease Spectrum (hepatic Cancer Progression) Tissue Array, Including TNM, Clinical Stage And Pathology Grade, 80 Cases/80 Cores, Replacing LV8011)をご紹介します。
※ヒト組織アレイは、ドナーからインフォームドコンセントを取得した組織を使用しています。
※ドナーの組織は、HIVおよびHepatitis Bが陰性であることを確認しています。
※本製品は研究用です。研究用以外には使用できません。
カートに商品を
追加しました。
追加しました。
ヒト組織アレイの価格
[在庫・価格 ：2024年05月16日 20時55分現在]
※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
| 詳細 | 商品名 |
|
文献数 | ||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Liver disease spectrum(hepatic cancer progression) tissue array, including TNM, clinical stage and pathology grade, ・・・ |
|
0 | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
[在庫・価格 ：2024年05月16日 20時55分現在]
※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
Liver disease spectrum(hepatic cancer progression) tissue array, including TNM, clinical stage and pathology grade, ・・・
文献数： 0
- 商品コード：LV8011a
- メーカー：USB
- 包装：1slide
- 価格：¥53,000
- 在庫：無(未発注)
- 納期：2～3週間 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等：
| 説明文 | |||
|---|---|---|---|
| 法規制等 | |||
| 保存条件 | 室温,暗所保存 | 法規備考 | |
| 掲載カタログ |
|
||
| 製品記事 |
TissueArray.Com社 組織アレイ(Tissue array) 選択ガイド |
||
| 関連記事 |
TissueArray.Com社 パラフィン組織スライド／組織アレイの仕様変更につきまして |
||
カートに商品を
追加しました。
追加しました。
ヒト組織アレイの特長
| Microarray Panel: | Liver disease spectrum (hepatic cancer progression) tissue microarray, containing 30 cases of hepatocellular carcinoma, 12 cholangiocellular carcinoma, 5 metastatic carcinoma, 23 liver cirrhosis and hepatitis, 5 each of adjacent normal tissue and normal tissue, single core per case | |
|---|---|---|
| Cores: | 80 | 
|
| Cases: | 80 | |
| Layout: | 10 cols × 8 rows | |
| Core Diameter: | 1.5 mm | |
| Thickness: | 5 µm | |
| Quality Control: | H&E and IHC confirmed | |
| Applications: | Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page. |
|
| Notes: | 1. TMA slides were sectioned and stored at 4C, may not be fresh cut. Please request fresh cut if experiment involves phosphor-specific antibodies, FISH or ISH, etc., minimal 3 slides be purchased of each TMA apllies to cover the cost of trimming for the fresh sectioning. 2. Most of TMA slides were not coated with extra layer of paraffin (tissue cores can be easily seen on the glass), but it is still recommended 30 min. of baking at 60C before putting into xylene for de-paraffinization procedure. |
|
*Tissue Microarray Slide Types:
- Unstained: unstained paraffin tissue microarray slide.
- Trial: tissue microarray trial slide. 10% - 25% of cores missing. Good for titrating antibody dilution and experiment conditions. Limited numbers are available, to 2 per item per order. Test slides (tissue arrays with catalog numbers ending with 241 or 242) are recommended as a substitute.
- H and E: Hematoxylin and Eosin stained tissue array slide.
カートに商品を
追加しました。
追加しました。
ヒト組織アレイの仕様表
| Pos | No. | Sex | Age | Organ | Pathology diagnosis | Grade | Stage | TNM | Type † |
|---|---|---|---|---|---|---|---|---|---|
| A1 | 1 | M | 46 | Liver | Hepatocellular carcinoma | 1 | II | T2N0M0 | Malignant |
| A2 | 2 | F | 98 | Liver | Hepatocellular carcinoma | 2 | IIIA | T3N0M0 | Malignant |
| A3 | 3 | M | 56 | Liver | Hepatocellular carcinoma | 1 | II | T2N0M0 | Malignant |
| A4 | 4 | F | 32 | Liver | Hepatocellular carcinoma | 2 | IIIA | T3N0M0 | Malignant |
| A5 | 5 | M | 35 | Liver | Hepatocellular carcinoma | 1 | II | T2N0M0 | Malignant |
| A6 | 6 | M | 49 | Liver | Hepatocellular carcinoma | 3 | IIIA | T3N0M0 | Malignant |
| A7 | 7 | M | 62 | Liver | Hepatocellular carcinoma | 3 | IIIA | T3N0M0 | Malignant |
| A8 | 8 | M | 71 | Liver | Hepatocellular carcinoma | 2 | IIIA | T3N0M0 | Malignant |
| A9 | 9 | M | 56 | Liver | Hepatocellular carcinoma | 2 | IIIA | T3N0M0 | Malignant |
| A10 | 10 | F | 45 | Liver | Hepatocellular carcinoma | 2 | IIIA | T3N0M0 | Malignant |
| B1 | 11 | M | 77 | Liver | Hepatocellular carcinoma | 1 | II | T2N0M0 | Malignant |
| B2 | 12 | M | 36 | Liver | Hepatocellular carcinoma | 2 | II | T2N0M0 | Malignant |
| B3 | 13 | M | 45 | Liver | Hepatocellular carcinoma | 2 | IIIA | T3N0M0 | Malignant |
| B4 | 14 | M | 39 | Liver | Hepatocellular carcinoma | 2 | II | T2N0M0 | Malignant |
| B5 | 15 | M | 38 | Liver | Hepatocellular carcinoma | 2 | IIIA | T3N0M0 | Malignant |
| B6 | 16 | M | 35 | Liver | Hepatocellular carcinoma | 2 | IIIA | T3N0M0 | Malignant |
| B7 | 17 | M | 63 | Liver | Hepatocellular carcinoma | 2 | IIIA | T3N0M0 | Malignant |
| B8 | 18 | M | 58 | Liver | Hepatocellular carcinoma | 2 | IIIA | T3N0M0 | Malignant |
| B9 | 19 | F | 55 | Liver | Hepatocellular carcinoma | 1 | IIIA | T3N0M0 | Malignant |
| B10 | 20 | F | 37 | Liver | Hepatocellular carcinoma (sparse) | 2 | IIIA | T3N0M0 | Malignant |
| C1 | 21 | M | 49 | Liver | Hepatocellular carcinoma | 2 | IIIA | T3N0M0 | Malignant |
| C2 | 22 | M | 53 | Liver | Hepatocellular carcinoma | 2 | IIIA | T3N0M0 | Malignant |
| C3 | 23 | F | 63 | Liver | Hepatocellular carcinoma | 1 | II | T2N0M0 | Malignant |
| C4 | 24 | F | 43 | Liver | Hepatocellular carcinoma | – | IIIC | T4N0M0 | Malignant |
| C5 | 25 | M | 50 | Liver | Hepatocellular carcinoma | 3 | II | T2N0M0 | Malignant |
| C6 | 26 | M | 52 | Liver | Hepatocellular carcinoma | 3 | IIIA | T3N0M0 | Malignant |
| C7 | 27 | M | 37 | Liver | Hepatocellular carcinoma | 3 | IIIA | T3N0M0 | Malignant |
| C8 | 28 | F | 52 | Liver | Hepatocellular carcinoma | 3 | IIIA | T3N0M0 | Malignant |
| C9 | 29 | M | 50 | Liver | Hepatocellular carcinoma | 3 | IIIA | T3N0M0 | Malignant |
| C10 | 30 | M | 37 | Liver | Hepatocellular carcinoma | 3 | IIIA | T3N0M0 | Malignant |
| D1 | 31 | M | 66 | Liver | Cholangiocellular carcinoma | 2–3 | II | T2N0M0 | Malignant |
| D2 | 32 | F | 36 | Liver | Cholangiocellular carcinoma (sparse) | – | II | T2N0M0 | Malignant |
| D3 | 33 | F | 62 | Liver | Cholangiocellular carcinoma | 2 | II | T2N0M0 | Malignant |
| D4 | 34 | F | 58 | Liver | Cholangiocellular carcinoma | 2 | II | T2N0M0 | Malignant |
| D5 | 35 | M | 40 | Liver | Cholangiocellular carcinoma | 2 | IIIA | T3N0M0 | Malignant |
| D6 | 36 | F | 40 | Liver | Cholangiocellular carcinoma | 2 | IIIA | T3N0M0 | Malignant |
| D7 | 37 | M | 45 | Liver | Cholangiocellular carcinoma | 2 | II | T2N0M0 | Malignant |
| D8 | 38 | F | 69 | Liver | Cholangiocellular carcinoma | 2 | I | T1N0M0 | Malignant |
| D9 | 39 | F | 58 | Liver | Cholangiocellular carcinoma | 3 | II | T2N0M0 | Malignant |
| D10 | 40 | F | 55 | Liver | Cholangiocellular carcinoma | 3 | IIIB | T3N1M0 | Malignant |
| E1 | 41 | F | 48 | Liver | Cholangiocellular carcinoma | 3 | II | T2N0M0 | Malignant |
| E2 | 42 | F | 70 | Liver | Cholangiocellular carcinoma | 3 | II | T2N0M0 | Malignant |
| E3 | 43 | M | 35 | Abdominal cavity | Metastatic hepatocellular carcinoma | 3 | – | – | Malignant |
| E4 | 44 | M | 41 | Pelvic cavity | Metastatic hepatocellular carcinoma | 3 | – | – | Malignant |
| E5 | 45 | M | 55 | Right chest wall | Metastatic hepatocellular carcinoma | 3 | – | – | Malignant |
| E6 | 46 | F | 56 | Colon | Metastatic hepatocellular carcinoma | – | – | – | Malignant |
| E7 | 47 | F | 33 | Left chest wall | Metastatic hepatocellular carcinoma | 2 | – | – | Malignant |
| E8 | 48 | M | 50 | Liver | Liver cirrhosis | – | – | – | Hyperplasia |
| E9 | 49 | M | 42 | Liver | Liver cirrhosis | – | – | – | Hyperplasia |
| E10 | 50 | M | 56 | Liver | Liver cirrhosis | – | – | – | Hyperplasia |
| F1 | 51 | M | 44 | Liver | Liver cirrhosis | – | – | – | Hyperplasia |
| F2 | 52 | M | 51 | Liver | Liver cirrhosis | – | – | – | Hyperplasia |
| F3 | 53 | M | 55 | Liver | Liver cirrhosis | – | – | – | Hyperplasia |
| F4 | 54 | F | 56 | Liver | Liver cirrhosis | – | – | – | Hyperplasia |
| F5 | 55 | M | 50 | Liver | Liver cirrhosis | – | – | – | Hyperplasia |
| F6 | 56 | M | 43 | Liver | Chronic active hepatitis | – | – | – | Inflammation |
| F7 | 57 | M | 68 | Liver | Chronic persistent hepatitis | – | – | – | Inflammation |
| F8 | 58 | M | 54 | Liver | Chronic active hepatitis | – | – | – | Inflammation |
| F9 | 59 | F | 56 | Liver | Chronic active hepatitis | – | – | – | Inflammation |
| F10 | 60 | M | 50 | Liver | Chronic active hepatitis | – | – | – | Inflammation |
| G1 | 61 | M | 50 | Liver | Chronic active hepatitis | – | – | – | Inflammation |
| G2 | 62 | F | 48 | Liver | Chronic active hepatitis | – | – | – | Inflammation |
| G3 | 63 | M | 43 | Liver | Liver cirrhosis | – | – | – | Hyperplasia |
| G4 | 64 | M | 58 | Liver | Liver cirrhosis | – | – | – | Hyperplasia |
| G5 | 65 | M | 43 | Liver | Liver cirrhosis | – | – | – | Hyperplasia |
| G6 | 66 | F | 52 | Liver | Liver cirrhosis | – | – | – | Hyperplasia |
| G7 | 67 | M | 57 | Liver | Liver cirrhosis | – | – | – | Hyperplasia |
| G8 | 68 | F | 55 | Liver | Liver cirrhosis | – | – | – | Hyperplasia |
| G9 | 69 | F | 32 | Liver | Liver cirrhosis | – | – | – | Hyperplasia |
| G10 | 70 | M | 63 | Liver | Liver cirrhosis | – | – | – | Hyperplasia |
| H1 | 71 | F | 57 | Liver | Adjacent normal hepatic tissue | – | – | – | NAT |
| H2 | 72 | M | 60 | Liver | Adjacent normal hepatic tissue | – | – | – | NAT |
| H3 | 73 | M | 31 | Liver | Adjacent normal hepatic tissue | – | – | – | NAT |
| H4 | 74 | F | 56 | Liver | Adjacent normal hepatic tissue | – | – | – | NAT |
| H5 | 75 | M | 31 | Liver | Adjacent normal hepatic tissue | – | – | – | NAT |
| H6 | 76 | F | 27 | Liver | Normal hepatic tissue | – | – | – | Normal |
| H7 | 77 | M | 35 | Liver | Normal hepatic tissue | – | – | – | Normal |
| H8 | 78 | M | 43 | Liver | Normal hepatic tissue | – | – | – | Normal |
| H9 | 79 | M | 47 | Liver | Normal hepatic tissue | – | – | – | Normal |
| H10 | 80 | F | 21 | Liver | Normal hepatic tissue | – | – | – | Normal |
| – | – | M | 42 | Adrenal gland | Pheochromocytoma (tissue marker) | – | Malignant |
*For precise diagnosis, refer to pathology description.
カートに商品を
追加しました。
追加しました。
ヒト組織アレイのFAQ
カートに商品を
追加しました。
追加しました。
製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。